Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinomaMasatoshi Kudo, Kiwamu Okita, Kazuho Imanaka et al.|European Journal of Cancer|2011Cited by 573
Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responsesTetsuo Takehara, Norio Hayashi|Gastroenterology|2004Cited by 220
Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patientsAkihiro Matsumoto, Shiro Iino, Akinori Rokuhara et al.|Hepatology Research|2005Cited by 192
The Bcl-Xl Inhibitor, ABT-737, Efficiently Induces Apoptosis and Suppresses Growth of Hepatoma Cells in Combination with SorafenibHayato Hikita, Norio Hayashi|Hepatology|2010Cited by 149
Sorafenib inhibits the shedding of major histocompatibility complex class I–related chain A on hepatocellular carcinoma cells by down‐regulating a disintegrin and metalloproteinase 9†Keisuke Kohga, Norio Hayashi|Hepatology|2009Cited by 147